MVM Life Science Partners
VC Fund
London, United Kingdom
MVM Life Science Partners is a VC fund in London focused on Health Care and Medical. MVM manages four funds totaling more than US$700 million. MVM has invested in biopharmaceuticals, diagnostics, drug delivery, gene therapy, healthcare services, medical devices, OTC medicines, research tools and vaccines.
- Total investments:
- 81
- Last investment:
- Lead investor:
- 46%
- Fund size:
- $500M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries MVM Life Science Partners invests in
Stages MVM Life Science Partners invests in
Countries MVM Life Science Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Series B
- $7M–$42M
- Series C
- $12M–$45M
Investment Focus
Industry
- Health Care 35 (43%)
- Medical 27 (33%)
- Biotechnology 27 (33%)
- Medical Device 23 (28%)
- Pharmaceutical 11 (14%)
Stage
- Funding Round 21 (26%)
- Series B 12 (15%)
- Series C 12 (15%)
- Series A 10 (12%)
- Series D 5 (6%)
Country
- United States 27 (33%)
- United Kingdom 11 (14%)
- Switzerland 3 (4%)
- Germany 2 (2%)
- Ireland 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anna Norrington
Head of Investor Communications
|
Head of Investor Communications | Total investments: 0 | Find email | |
Hugo Harrod
Partner
|
Partner | Total investments: 9 | Find email | |
Neil Akhurst
Finance Partner
|
Finance Partner | Total investments: 0 | Find email | |
Stephen Reeders
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 0 | Find email | |
Stephen Reeders
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 8 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| GT Medical Technologies is a medical technology company focused on improving outcomes for patients with brain tumors through treatment solutions. It was established by to address unmet needs in neuro-oncology and advance the standard of care for patients with operable brain tumors. The company's flagship product, GammaTile®, is an FDA-cleared,bioabsorbable collagen implant embedded with radiation seeds that delivers targeted radiation therapy directly to the surgical cavity immediately following tumor removal. By providing localized treatment at the time of surgery, GammaTile is designed to target residual cancer cells while reducing radiation exposure to surrounding healthy brain tissue. This approach aims to help prevent tumor recurrence and improve patient outcomes. | $100M / Series E / Jun 09, 2026 | ||
| Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal diseases. It was founded in 2015 by Brian Shields and David Townley in Oranmore, Galway, Ireland. | $74.5M / Series C / Feb 11, 2026 | ||
| Avanzanite Bioscience focuses on enhancing access to medicines for rare diseases in Europe. It operates as a commercial-stage enterprise, partnering with pharmaceutical companies like Advicenne and SIFI to facilitate the distribution and commercialization of orphan drugs. Avanzanite's collaborations extend across several European countries,including Ireland, Cyprus, Malta, Germany, and Austria, aiming to address the complexities and costs associated with the orphan drug market. The company's efforts are directed towards redefining the orphan drug landscape and unlocking new possibilities for patients suffering from rare diseases. | $37.1M / Series A / Nov 18, 2025 | ||
| ProVerum Medical is a healthcare company that develops innovative treatments for benign prostatic hyperplasia (BPH). ProVerum develops the ProVee System, which is a minimally invasive implant that gently opens the blocked part of the urethra without cutting, heating, or removing tissue. | $80M / Series B / Aug 25, 2025 | ||
| GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The company's first product, GammaTile™ is protected by 10 US and 2Canadian issued patents, and 1 EPO patent. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 120 patients with recurrent brain tumors in a clinical trial at Barrow Neurological Institute (BNI) and observed significant clinical improvement. | $53.3M / Series D / Jan 16, 2025 | ||
| OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians, and payors. Their vision is to provide the first credible replacement to metal implants in the $10B+ orthopedic fixation market (screws, pins, plates) with an Intelligent Bone Regeneration Technology. OSSIOfiber represents abreakthrough material platform for orthopedic and podiatric surgeons who seek a more biologically friendly way to restore patient stability and mobility with nothing permanent left behind.Founded in 2014, OSSIO began as the culmination of years of biomechanical research and a vision for the possibility of better bone healing. The technological basis of OSSIOfiber™ was developed and would lay the groundwork for ushering in a new breakthrough category of non-permanent fixation, “Bio-Integratives” hardware that has both desired strength AND bio-friendliness. Hardware that has the mechanical strength for easy insertion and secure fixation, while enabling the body to regrow bone, incorporating and replacing the implant (without the adverse inflammation and weakness often seen in “bio-resorbables and other “bio-composites”), has remained elusive to the industry until now. | $27.6M / Series D / Dec 02, 2024 | ||
| Icotec develops and produces carbon fiber reinforced plastic implants for spine surgeries and accident treatments. | $30M / Venture - Series Unknown / Jan 24, 2024 | ||
| Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people.The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS)and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California. | $85M / Series E / Jan 03, 2024 | ||
| Gynesonics is a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions. Gynesonics serves customers worldwide. It was founded in 2005 and is headquartered in Redwood City, California. | $42.5M / Oct 25, 2023 | ||
| BioProtect Ltd. is an international medical device startup. It is primarily engaged in to the business of developing and commercializing biodegradable balloon spacers for the protection of normal tissue during cancer radiation therapy. The company's current focus in the growing radiotherapy spacers market, where its ProSpace balloon spacer (CEmarked) has shown superior efficacy and safety in protecting the rectum during radiation therapy for prostate cancer. The company's technology platform of biodegradable implantable balloons suits a wide range of applications for unmet clinical needs. BioProtect was founded in the year 2004 and headquartered in Israel, with subsidiaries in Germany and US. | $28M / Sep 27, 2023 | ||
| See all 81 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does MVM Life Science Partners invest in?
MVM Life Science Partners invests primarily in Health Care, Medical and Biotechnology startups, most often at Funding Round and Series B stage. Most of the 81 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is MVM Life Science Partners's check size?
MVM Life Science Partners typically joins rounds of $7M–$42M at Series B and $12M–$45M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds MVM Life Science Partners participates in.
How do I contact MVM Life Science Partners?
Public channels for MVM Life Science Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at MVM Life Science Partners?
The team at MVM Life Science Partners includes Anna Norrington (Head of Investor Communications), Hugo Harrod (Partner) and Neil Akhurst (Finance Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
